LNTH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LNTH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net margin is calculated as Net Income divided by its Revenue. Lantheus Holdings's Net Income for the three months ended in Sep. 2024 was $131 Mil. Lantheus Holdings's Revenue for the three months ended in Sep. 2024 was $379 Mil. Therefore, Lantheus Holdings's net margin for the quarter that ended in Sep. 2024 was 34.61%.
The historical rank and industry rank for Lantheus Holdings's Net Margin % or its related term are showing as below:
The historical data trend for Lantheus Holdings's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Net Margin % | Get a 7-Day Free Trial | 9.12 | -3.97 | -16.76 | 3.00 | 25.20 |
Lantheus Holdings Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Net Margin % | Get a 7-Day Free Trial | 41.24 | 29.20 | 35.43 | 15.75 | 34.61 |
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Net Margin % distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's Net Margin % falls into.
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
Lantheus Holdings's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as
Net Margin | = | Net Income (A: Dec. 2023 ) | / | Revenue (A: Dec. 2023 ) |
= | 326.661 | / | 1296.429 | |
= | 25.20 % |
Lantheus Holdings's Net Margin for the quarter that ended in Sep. 2024 is calculated as
Net Margin | = | Net Income (Q: Sep. 2024 ) | / | Revenue (Q: Sep. 2024 ) |
= | 131.093 | / | 378.734 | |
= | 34.61 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings (NAS:LNTH) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Thank you for viewing the detailed overview of Lantheus Holdings's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Marshall Robert J. Jr. | officer: CFO and Treasurer | C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862 |
Paul Blanchfield | officer: Chief Commercial Officer | C/O LANTHEUS HOLDINGS, INC., 331, NORTH BILLERICA MA 01862 |
Mary Anne Heino | director, officer: CEO and President | C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862 |
James H Thrall | director | 343 COMMERCIAL STREET #314, BOSTON MA 02109 |
Daniel Niedzwiecki | officer: See Remarks | C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862 |
Gerard Ber | director | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169 |
Andrea Sabens | officer: Chief Accounting Officer | C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862 |
Gary J Pruden | director | ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933 |
Heinz Christoph Maeusli | director | SCHUETZENWEG 3, ENGELBURG V8 9032 |
Julie Mchugh | director | C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Sam R Leno | director | C/O BOSTON SCIENTIFIC CORPORATION, ONE BOSTON SCIENTIFIC PLACE, NATICK MA 01760 |
Minnie Baylor-henry | director | C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803 |
Etienne Montagut | officer: See Remarks | C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862 |
Brian A Markison | director | 501 FIFTH STREET, BRISTOL TN 37620 |
Jean-claude Provost | officer: Chief Medical Officer | C/O LANTHEUS HOLDINGS, INC., 201 BURLINGTON RD, SOUTH BUILDING, BEDFORD MA 01730 |
From GuruFocus
By Marketwired • 11-06-2024
By Marketwired • 11-20-2024
By GuruFocus News • 11-04-2024
By GuruFocus News • 11-11-2024
By GuruFocus News • 11-15-2024
By GuruFocus News • 11-22-2024
By GuruFocus Research • 08-01-2024
By Marketwired • 09-05-2024
By Marketwired • 07-31-2024
By GuruFocus News • 11-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.